Pre-Made Interferon Gamma Biosimilar, Recombinant Protein targeting IFNGR1: Recombinant therapeutic protein targeting CD119/IFNGR/IMD27A/IMD27B for drug discovery and mechanism of action (MOA) research

Pre-Made Interferon Gamma Biosimilar, Recombinant Protein targeting IFNGR1: Recombinant therapeutic protein targeting CD119/IFNGR/IMD27A/IMD27B is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

IFN-γ, or type II interferon, is a cytokine that is critical for innate and adaptive immunity against viral, some bacterial and protozoan infections. IFN-γ is an important activator of macrophages and inducer of major histocompatibility complex class II molecule expression.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-874-1mg	1mg	3090
GMP-Bios-INN-874-10mg	10mg	Inquiry
GMP-Bios-INN-874-100mg	100mg	Inquiry
GMP-Bios-INN-874-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Interferon Gamma Biosimilar, Recombinant Protein targeting IFNGR1: Recombinant therapeutic protein targeting CD119/IFNGR/IMD27A/IMD27B
INN Name	Interferon Gamma
Target	IFNGR1
Format	Recombinant Protein
Derivation	0
Species Reactivity	human
CH1 Isotype	IFNG (interferon gamma, IFN gamma)
VD LC	IFNG (interferon gamma, IFN gamma)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Vidara Therapeutics Ltd. (Dublin Ireland) / Horizon Therapeutics plc (Dublin Ireland)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0